Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA

References

• National Cancer InstituteSEER stat fact sheets: Lung and bronchus cancer Available from: http://seer.cancer.gov/statfacts/html/lungb.htmlAccessed November 18, 2015
   Google Scholar
• RamalingamSBelaniCSystemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directionsOncologist200813Suppl 151318263769
   PubMed Web of Science ®Google Scholar
• O’BryantCLWengerSDKimMThompsonLACrizotinib: a new treatment option of ALK-positive non-small cell lung cancerAnn Pharmacother201347218919723386065
   PubMed Web of Science ®Google Scholar
• RadzikowskaERoszkowski-SlizKChabowskiMGlazPInfluence of delays in diagnosis and treatment on survival in small cell lung cancer patientsAdv Exp Med Biol201378835536223835998
   PubMed Web of Science ®Google Scholar
• DempkeWCTargeted therapy for NSCLC-A double-edged Sword?Anticancer Res20153552503251225964523
   PubMed Web of Science ®Google Scholar
• ShepherdFSecond-line chemotherapy for non-small cell lung cancerExpert Rev Anticancer Ther20033143544212934656
   PubMedGoogle Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small cell lung cancerJ Clin Oncol200826213543345118506025
   PubMed Web of Science ®Google Scholar
• DempkeWCSutoTReckMTargeted therapies for non-small cell lung cancerLung Cancer201067325727419914732
   PubMed Web of Science ®Google Scholar
• MaWGilliganBMYuanJLiTCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyJ Hematol Oncol2016914727234522
   PubMed Web of Science ®Google Scholar
• DholariaBHammondWShredersALouYEmerging therapeutic agents for lung cancerJ Hematol Oncol20169113827938382
   PubMed Web of Science ®Google Scholar
• DiggsLPHsuehECUtility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor responseBiomark Res2017511228331612
   PubMed Web of Science ®Google Scholar
• MinguetJSmithKHBramlagePTargeted therapies for treatment of non-small cell lung cancer – recent advances and future perspectivesInt J Cancer2016138112549256126537995
   PubMed Web of Science ®Google Scholar
• SolomonBVarella-GarciaMCamidgeDRALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerJ Thorac Oncol20094121450145420009909
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuSHALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res201319154273428123729361
   PubMed Web of Science ®Google Scholar
• CasaluceFSgambatoAMaionePALK inhibitors: a new targeted therapy in the treatment of advanced NSCLCTarg Oncol2013815567
   Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther2007612 Pt 13314332218089725
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib vs chemotherapy in advanced ALK-positive lung cancerN Engl J Med20133682385239423724913
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib vs chemotherapy in ALK-positive lung cancerN Engl J Med20143712132167217725470694
   PubMed Web of Science ®Google Scholar
• ToyokawaGSetoTALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Clin Lung Cancer201415531331924984564
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• WeickhardtAJScheierBBurkeJMLocal ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancerJ Thorac Oncol20127121807181423154552
   PubMed Web of Science ®Google Scholar
• WuJSavoojiJLiuDSecond- and third-generation ALK inhibitors for non-small cell lung cancerJ Hematol Oncol201691926951079
   PubMed Web of Science ®Google Scholar
• IragavarapuCMustafaMAkinleyeANovel ALK inhibitors in clinical use and developmentJ Hematol Oncol201581725888090
   PubMed Web of Science ®Google Scholar
• KodamaTHasegawaMTakanashiKSakuraiYKondohOSakamotoHAntitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesCancer Chemother Pharmacol20147451023102825205428
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisLAlectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II Global StudyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSstudy investigatorsAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group,multicentre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• YangJCOuSIDe PetrisLPooled systemic efficacy and safety data from two phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer (NSCLC)J Thorac Oncol201712101552156028689043
   PubMed Web of Science ®Google Scholar
• GadgeelSMGandhiLRielyGJSafety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyLancet Oncol201415101119112825153538
   PubMed Web of Science ®Google Scholar
• BendalyESasaneMZhangJSwallowEMacalaladARPatelDDiverse characteristics of the ALK+ NSCLC patients in the United StatesPoster presented at: The 16th World Conference on Lung CancerSeptember 2015Denver, CO
   Google Scholar
• BettsKSongJGuoJWongWRaveloASchulzMReal-world treatment patterns and brain metastases development in ALK-positive non-small cell lung cancerPoster presented at: The Association of Managed Care Pharmacist (AMCP) Annual Managed Care and Specialty Pharmacy Annual MeetingApril 2016San Fransisco, CA
   Google Scholar
• GuérinASasaneMZhangJBrain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burdenJ Med Econ201518431232225565443
   PubMed Web of Science ®Google Scholar
• DoebeleRCLuXSumeyCOncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancerCancer2012118184502451122282022
   PubMed Web of Science ®Google Scholar
• RangachariDYamaguchiNVanderLaanPABrain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersLung Cancer201588110811125682925
   PubMed Web of Science ®Google Scholar
• ToyokawaGSetoTTakenoyamaMIchinoseYInsights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Cancer Metastasis Rev201534479780526342831
   PubMed Web of Science ®Google Scholar
• Barnholtz-SloanJSSloanAEDavisFGVigneauFDLaiPSawayaREIncidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance systemJ Clin Oncol200422142865287215254054
   PubMed Web of Science ®Google Scholar
• JenaATanejaSTalwarVSharmaJBMagnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptomJ Thorac Oncol20083214014418303434
   PubMed Web of Science ®Google Scholar
• BaikCSChamberlainMCChowLQTargeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancerJ Thorac Oncol20151091268127826107553
   PubMed Web of Science ®Google Scholar